| 2026-09-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-10 | Press release | Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results |
| 2026-08-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-10 | 8-K | Form 8-K, Item 8.01 |
| 2026-08-10 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-06-30 | Press release | Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosi |
| 2026-06-12 | Press release | Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematol |
| 2026-06-12 | Press release | Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advan |
| 2026-06-11 | 8-K | Form 8-K, Item 5.07 |
| 2026-05-30 | Press release | Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combinati |
| 2026-05-28 | Press release | Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Comb |
| 2026-05-27 | Press release | Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference |
| 2026-05-12 | Deck | May 2026 Corporate Presentation |
| 2026-05-12 | Press release | Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress |
| 2026-05-05 | Press release | Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results |
| 2026-05-05 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-05 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| 2026-04-23 | Proxy | Definitive proxy statement |
| 2026-04-21 | Press release | Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) |
| 2026-04-01 | Press release | Press release · Apr 2026 |
| 2026-03-16 | Press release | Press release · Mar 2026 |
| 2026-02-28 | Press release | Press release · Feb 2026 |
| 2026-02-17 | Press release | Press release · Q4 2025 · Feb 2026 |
| 2026-02-17 | 8-K | Form 8-K, Item 2.02 results |
| 2026-02-17 | 10-K | Annual report on Form 10-K, FY25 |
| 2026-02-10 | Press release | Press release · Feb 2026 |
| 2026-01-26 | Press release | Press release · Jan 2026 |
| 2026-01-20 | Press release | Press release · Jan 2026 |
| 2026-01-12 | Press release | Press release · Jan 2026 |
| 2026-01-06 | Press release | Press release · Jan 2026 |
| 2025-12-08 | Deck | Investor presentation · Dec 2025 |
| 2025-12-08 | 8-K | Form 8-K, Item 8.01 |
| 2025-11-18 | 8-K | Form 8-K, Item 1.01 |
| 2025-11-13 | 8-K | Form 8-K, Item 1.01 |
| 2025-11-10 | Deck | Investor presentation · Nov 2025 |
| 2025-11-10 | 8-K | Form 8-K, Item 7.01 |
| 2025-11-07 | 10-Q | Form 10-Q for the quarter ended Sep 30 |
| 2025-11-03 | 8-K | Form 8-K, Item 2.02 results |
| 2025-09-11 | 8-K | Form 8-K, Item 1.01 |
| 2025-08-05 | 8-K | Form 8-K, Item 2.02 results |